BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees. To have the...
BioCentury | Aug 4, 2020
Product Development

Warp Speed, decentralized trials & SPACs: a BioCentury podcast

After pledging up to $2.1 billion to a preclinical vaccine from Sanofi and GSK, the U.S. government’s total commitment for COVID-19 vaccine candidates now stands at $8.3 billion across seven vaccines based on four different...
BioCentury | Jun 22, 2020

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

...what to do,” Codiak President and CEO Doug Williams told BioCentury. “If we crack that nut...
...Sarepta partnership could equip Codiak to pursue other gene therapies independently. “If we crack that nut...
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy in Phase I/II testing for egg allergy; the company also has a preclinical tree nut...
BioCentury | Aug 26, 2019
Product Development

Vax to the future: How Anthony Fauci is thinking about next-gen vaccines and other NIAID priorities

From his vantage point overseeing NIH’s infectious disease agenda, Anthony Fauci has identified vaccine development as an area poised to make big leaps. He says the institute’s prioritization of platform technologies holds more promise than...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BioCentury | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Aug 29, 2018
Emerging Company Profile

Meta(bolite) analysis

ClostraBio Inc.’s preclinical gut microbiome-derived metabolites could yield a pan-allergen therapy for food allergy, eschewing the need for multiple allergen-specific treatments. Director of Operations John Colson said research from co-founder and President Cathryn Nagler suggests...
BioCentury | May 5, 2018

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
Items per page:
1 - 10 of 92